The ThermiSmooth treatment has been performed for several years, with no significant complications (beyond swelling and redness)
PMID: 33670644
Product Specifications Test Results Sample: Tesa, Ipamorelin, BPC-157 8/2/2mg Certificate of Analysis Certificate of Analysis (Endotoxin) Third-party tested for ~99% purity Tesa Properties Source: PubChem Form: Lyophilized powder Unit size: 8mg/vial Unit quantity: 1 vial Molecular formula: C 223 H 370 N 72 O 69 S Molecular weight: 5196 g/mol Synonym: Tesamorelin acetate Sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL CAS number: 901758-09-6 Ipamorelin Properties Source: PubChem Form: Lyophilized powder Unit size: 2mg/vial Unit quantity: 1 vial Molecular formula: C 38 H 49 N 9 O 5 Molecular weight: 711.9 g/mol Sequence: Aib-His-D-2-Nal-D-Phe-Lys CAS number: 170851-70-4 BPC-157 Properties Source: PubChem Form: Lyophilized powder Unit size: 2mg/vial Unit quantity: 1 vial Molecular formula: C 62 H 98 N 16 O 22 Molecular weight: 1419.5 g/mol Synonym: Bepecin Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val CAS number: 137525-51-0 Frequently Asked Questions Related Products 3 of 45 products KPV (10mg) PNC-27 (10mg) How It Works Precision Synthesis Synthesized in dedicated, state of-the-art facilities
Learn what it's, how it works, dosing basics, what to expect, and how to get started safely
1998 GHRH-R signals via cAMP/PKA while GHSR-1a signals via PLC/IP3 distinct second messenger cascades that do not compete
Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive
